JPMorgan Chase & Co. Boosts Cognex (NASDAQ:CGNX) Price Target to $65.00

Key Points

• JPMorgan raised Cognex's price target to $65 (from $55) but kept a "neutral" rating, matching a MarketBeat consensus target of $65 while other analysts' targets vary up to $75.
• Cognex beat Q1 expectations with $0.34 EPS and ~24% revenue growth and guided Q2 to $0.40–$0.44 EPS, but the stock's high valuation (~78x P/E) and recent insider selling pose downside risk.

Cognex (NASDAQ:CGNX - Get Free Report) had its price target increased by analysts at JPMorgan Chase & Co. from $55.00 to $65.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a "neutral" rating on the scientific and technical instruments company's stock. JPMorgan Chase & Co.'s price objective would suggest a potential downside of 0.37% from the stock's previous close.

Other equities analysts have also issued reports about the stock. Robert W. Baird set a $72.00 price objective on shares of Cognex in a report on Friday. Citigroup reaffirmed a "neutral" rating on shares of Cognex in a report on Friday. Zacks Research downgraded Cognex from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 14th. Wall Street Zen lowered Cognex from a "buy" rating to a "hold" rating in a research report on Saturday, April 11th. Finally, Stephens lifted their price objective on Cognex from $65.00 to $75.00 and gave the stock an "overweight" rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $65.00.

Cognex Stock Down 1.0%

CGNX stock traded down $0.68 during midday trading on Friday, reaching $65.24. The stock had a trading volume of 2,068,006 shares, compared to its average volume of 2,190,552. The firm has a market cap of $10.90 billion, a price-to-earnings ratio of 77.58 and a beta of 1.48. Cognex has a twelve month low of $29.00 and a twelve month high of $71.90. The business has a fifty day simple moving average of $52.67 and a two-hundred day simple moving average of $45.20.

Cognex (NASDAQ:CGNX - Get Free Report) last released its earnings results on Wednesday, May 6th. The scientific and technical instruments company reported $0.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.25 by $0.09. The company had revenue of $268.44 million for the quarter, compared to the consensus estimate of $245.98 million. Cognex had a net margin of 13.62% and a return on equity of 10.86%. The company's revenue was up 24.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.14 EPS. Cognex has set its Q2 2026 guidance at 0.400-0.440 EPS. On average, equities analysts predict that Cognex will post 0.97 earnings per share for the current fiscal year.

Insider Buying and Selling at Cognex

In other Cognex news, Director Robert Willett sold 177,052 shares of Cognex stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $58.39, for a total value of $10,338,066.28. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Angelos Papadimitriou sold 4,150 shares of the business's stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $55.58, for a total value of $230,657.00. Following the completion of the sale, the director owned 16,222 shares in the company, valued at approximately $901,618.76. This trade represents a 20.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 196,083 shares of company stock valued at $11,419,321 in the last 90 days. 1.70% of the stock is currently owned by company insiders.

Institutional Trading of Cognex

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Quent Capital LLC bought a new position in Cognex in the third quarter valued at $26,000. REAP Financial Group LLC acquired a new stake in Cognex in the 3rd quarter valued at $27,000. Geneos Wealth Management Inc. lifted its position in Cognex by 402.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 919 shares of the scientific and technical instruments company's stock worth $27,000 after buying an additional 736 shares in the last quarter. CIBC Private Wealth Group LLC lifted its position in Cognex by 74.8% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 764 shares of the scientific and technical instruments company's stock worth $35,000 after buying an additional 327 shares in the last quarter. Finally, Cassaday & Co Wealth Management LLC acquired a new position in shares of Cognex during the 1st quarter worth about $36,000. 88.12% of the stock is currently owned by institutional investors and hedge funds.

Key Cognex News

Here are the key news stories impacting Cognex this week:

• Positive Sentiment: Q1 beat and upbeat Q2 guide — Cognex reported Q1 revenue up ~24% and EPS of $0.34 (vs. Street ~ $0.25), with margin expansion and management citing broad-based demand plus new AI-powered In-Sight vision systems; Q2 guidance of $280–$300M revenue and $0.40–$0.44 EPS points to continued momentum. CGNX Q1 Earnings Beat Estimates on Broad-Based Demand Strength
• Positive Sentiment: Analyst upgrades lift sentiment — Stephens and Needham raised price targets to $75 and issued overweight/buy calls, signaling Wall Street is pricing in further upside from automation and logistics demand. Cognex NASDAQ: CGNX Given New $75.00 Price Target at Stephens Needham raises target to $75
• Positive Sentiment: Elevated call option activity — unusually large call volume (over 9k contracts) shows speculative/hedged bullish positioning around the earnings/guidance beat, which can amplify intraday upside.
• Neutral Sentiment: Dividend declared — board approved a $0.085 quarterly dividend (ex‑dividend May 21, payable June 4). Small yield; supportive but not a major driver.
• Neutral Sentiment: Market coverage and valuation debate — commentary and deep-dive pieces are asking whether the post‑surge rally (roughly +121% one year) leaves upside limited, prompting mixed investor views on near-term buy-in. Is It Too Late To Consider Cognex (CGNX) After A 121% One Year Surge?
• Negative Sentiment: Insider selling and high valuation — recent filings show multiple insider sales in the past six months; combined with a stretched P/E (~78x) after the rally, this raises risk that expectations are high and could weigh on the stock if growth normalizes. Cognex shares jump on Q1 beat and upbeat Q2 outlook

About Cognex

Cognex Corporation is a leading provider of machine vision systems, software, sensors and industrial barcode readers used to automate manufacturing, logistics and distribution processes. The company designs and develops vision-based products that help manufacturers and logistics operators inspect, identify and guide parts, assemblies and packaged goods in real time. Its solutions are applied in a broad range of industries, including automotive, electronics, semiconductor, pharmaceutical, food and beverage, and general manufacturing.

The company's product portfolio includes stand-alone vision systems, vision sensors and deep learning-based software platforms that enable automated inspection, quality control and traceability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.